Monte Carlo study on the secondary cancer risk estimations for patients undergoing prostate radiotherapy: A humanoid phantom study
- PMID: 32021575
- PMCID: PMC6994283
- DOI: 10.1016/j.rpor.2019.12.029
Monte Carlo study on the secondary cancer risk estimations for patients undergoing prostate radiotherapy: A humanoid phantom study
Abstract
Aim: The aim of this study was to estimate the secondary malignancy risk from the radiation in FFB prostate linac-based radiotherapy for different organs of the patient.
Background: Radiation therapy is one of the main procedures of cancer treatment. However, the application the radiation may impose dose to organs of the patient which can be the cause of some malignancies.
Materials and methods: Monte Carlo (MC) simulation was used to calculate radiation doses to patient organs in 18 MV linear accelerator (linac) based radiotherapy. A humanoid MC phantom was used to calculate the equivalent dose s for different organs and probability of secondary cancer, fatal and nonfatal risk, and other risks and parameters related to megavoltage radiation therapy. In out-of-field radiation calculation, it could be seen that neutrons imparted a higher dose to distant organs, and the dose to surrounding organs was mainly due to absorbed scattered photons and electron contamination.
Results: Our results showed that the bladder and skin with 54.89 × 10-3 mSv/Gy and 46.09 × 10-3 mSv/Gy, respectively, absorbed the highest equivalent dose s from photoneutrons, while a lower dose was absorbed by the lung at 3.42 × 10-3 mSv/Gy. The large intestine and bladder absorbed 55.00 × 10-3 mSv/Gy and 49.08 × 10-3, respectively, which were the highest equivalent dose s due to photons. The brain absorbed the lowest out-of-field dose, at 1.87 × 10-3 mSv/Gy.
Conclusions: We concluded that secondary neutron portion was higher than other radiation. Then, we recommended more attention to neutrons in the radiation protection in linac based high energy radiotherapy.
Keywords: Equivalent dose; Monte Carlo simulation; Prostate radiotherapy; Radiation contamination; Secondary malignancy.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.
Figures





References
-
- Piedbois P., Bataini J.P., Colin P. Conventional megavoltage radiotherapy in the management of malignant epithelial tumours of the parotid gland. Radiother Oncol. 1989;16:203–209. - PubMed
-
- Lonski P., Ramachandran P., Franich R., Kron T. Surface dose measurements in and out of field: implications for breast radiotherapy with megavoltage photon beams. Z Med Phys. 2017;27(4):318–323. - PubMed
-
- Ghal–Eh N., Goudarzi H., Rahmani F. FLUKA simulation studies on in–phantom dosimetric parameters of a LINAC–based BNCT. Radiat Phys Chem. 2017;141:36–40.
-
- Cerón Ramírez P.V., Díaz Góngora J.A., Paredes Gutiérrez L.C., Rivera M.T., Vega Carrillo H.R. Neutron H*(10) estimation and measurements around 18MV linac. Appl Radiat Isot. 2016;117:2–7. - PubMed
LinkOut - more resources
Full Text Sources